



NATIONAL
GUIDELINE
CLEARINGHOUSE

NEATS Assessment NGC-11250 (up. NGC-9742)

Guideline Title

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for *CYP2D6* and *CYP2C19* genotypes and dosing of tricyclic antidepressants: 2016 update.

National Guideline Clearinghouse (NGC) has assessed this guideline's adherence to standards of trustworthiness, derived from the Institute of Medicine's report [Clinical Practice Guidelines We Can Trust](#).

=Poor =Fair =Good =Very Good =Excellent

NEATS ASSESSMENT

STANDARD OF TRUSTWORTHINESS

Yes

Disclosure of Guideline Funding Source



Disclosure and Management of Financial Conflicts of Interest (COI)

Yes

Guideline Development Group Composition: Multidisciplinary Group

Unknown

Guideline Development Group Composition: Methodologist Involvement



Guideline Development Group Composition: Patient and Public Perspectives



Use of a Systematic Review of Evidence: Search Strategy



Use of a Systematic Review of Evidence: Study Selection



Use of a Systematic Review of Evidence: Synthesis of Evidence



Evidence Foundations for and Rating Strength of Recommendations: Grading the Quality or Strength of Evidence



Evidence Foundations for and Rating Strength of Recommendations: Benefits and Harms of Recommendations



Evidence Foundations for and Rating Strength of Recommendations: Evidence Summary Supporting Recommendations



Evidence Foundations for and Rating Strength of Recommendations: Rating the Strength of Recommendations



Specific and Unambiguous Articulation of Recommendations



External Review



Updating